Net profit of Venus Remedies declined 4.97% to Rs 10.51 crore in the quarter ended March 2024 as against Rs 11.06 crore during the previous quarter ended March 2023. Sales rose 25.39% to Rs 195.16 crore in the quarter ended March 2024 as against Rs 155.64 crore during the previous quarter ended March 2023.For the full year,net profit rose 7.27% to Rs 28.49 crore in the year ended March 2024 as against Rs 26.56 crore during the previous year ended March 2023. Sales rose 8.27% to Rs 601.45 crore in the year ended March 2024 as against Rs 555.51 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales195.16155.64 25 601.45555.51 8 OPM %9.9815.81 -9.9110.80 - PBDT23.3728.02 -17 71.0970.22 1 PBT17.4619.73 -12 44.6537.92 18 NP10.5111.06 -5 28.4926.56 7 Powered by Capital Market - Live News

Venus Remedies will hold a meeting of the Board of Directors of the Company on 30 May 2024Powered by Capital Market - Live News

Net profit of Venus Remedies rose 108.21% to Rs 6.85 crore in the quarter ended December 2023 as against Rs 3.29 crore during the previous quarter ended December 2022. Sales rose 22.69% to Rs 143.42 crore in the quarter ended December 2023 as against Rs 116.90 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales143.42116.90 23 OPM %8.396.93 - PBDT14.3211.76 22 PBT7.784.54 71 NP6.853.29 108 Powered by Capital Market - Live News

Venus Remedies will hold a meeting of the Board of Directors of the Company on 14 February 2024.Powered by Capital Market - Live News

Venus Remedies announced dual achievements in securing marketing authorisations for three variants of Docetaxel in Israel and Cytarabjne 100MG in Colombia. Powered by Capital Market - Live News